1. The use of a transscrotal testosterone delivery system in the treatment of patients with weight loss related to human immunodeficiency virus infection∗ 
Adrian S Dobs, MD, Joseph Cofrancesco, MD, William E Nolten, MD, Ann Danoff, MD, Roger Anderson, MD, C Dukes Hamilton, MD, Judith Feinberg, MD, Daniel Seekins, MD, Bienvenido Yangco, MD, Frank Rhame, MD 
The American Journal of Medicine 
Volume 107, Issue 2, Pages (August 1999)
DOI: /S (99)00193-X

2. Figure 1
Morning serum total testosterone levels (mean with 95% confidence intervals) at baseline and weeks 4, 8, and 12. Testosterone-treated subjects are shown in diamonds, placebo in squares. The change in serum testosterone level from baseline to week 12 was significant for testosterone-treated subjects (P <0.01); there was no significant change for the placebo-treated subjects (P = 0.3).
The American Journal of Medicine  , DOI: ( /S (99)00193-X)

3. Figure 2
Morning serum free testosterone levels (mean with 95% confidence intervals) at baseline and weeks 4, 8, and 12. Testosterone-treated subjects are shown in diamonds, placebo in squares. The change in serum testosterone level from baseline to week 12 was significant for testosterone-treated subjects (P <0.01); there was no significant change for the placebo-treated subjects (P = 0.6).
The American Journal of Medicine  , DOI: ( /S (99)00193-X)